Literature DB >> 7053285

The 24-hour ambulatory blood pressure profile with verapamil.

B A Gould, S Mann, H Kieso, V B Subramanian, E B Raftery.   

Abstract

The blood pressure response in hypertensive subjects to chronic treatment with verapamil, a calcium antagonist (or, more precisely, a slow-channel inhibitor), was studied using the Oxford system for continuous monitoring of intraarterial blood pressure. Sixteen patients underwent continuous monitoring over a 48-hour period before and after at least 6 weeks of therapy (dose range 120-160 mg three times daily). Each monitoring period included physiologic tests designed to show the effects of different types of exercise. Verapamil produces a consistent reduction of blood pressure over 24 hours, but particularly during the day. Heart rate was similarly reduced. There was no evidence of postural hypotension, and the absolute responses to dynamic and isometric exercise were reduced. The degree of reduction of the blood pressure was consistent, suggesting that slow-channel inhibitors may be appropriate for antihypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7053285     DOI: 10.1161/01.cir.65.1.22

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  25 in total

1.  Acute and long-term hemodynamic effects of tiapamil at rest and during exercise in essential hypertension.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 2.  Calcium antagonists and chronic cardiac failure.

Authors:  M J Kendall; R C Horton; S R Smith
Journal:  Postgrad Med J       Date:  1986-08       Impact factor: 2.401

Review 3.  Calcium channel blocking agents and the heart.

Authors:  J Kenny
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-26

4.  A study of nadolol to determine its effect on ambulatory blood pressure over 24 hours, and during exercise testing.

Authors:  R S Hornung; B A Gould; H Kieso; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

5.  Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.

Authors:  Dong-Hyun Choi; Joong-Hwa Chung; Jun-Shik Choi
Journal:  Eur J Clin Pharmacol       Date:  2009-12-12       Impact factor: 2.953

6.  Sustained release verapamil in hypertension. Results from a noninvasive ambulatory blood pressure monitoring and a clinical study.

Authors:  A Nissinen; A Koistinen; J Tuomilehto; S Sundberg; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Tiapamil, a new calcium channel blocking agent for the treatment of effort induced chronic stable angina pectoris.

Authors:  N S Khurmi; C W Robinson; M J O'Hara; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris.

Authors:  N S Khurmi; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Hemodynamic effects of Ro 23-6152 in patients with essential hypertension.

Authors:  H B Folkers; J C van Zwienen; P Boer; C H Kleinbloesem; G G Geyskes
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Sodium intake does not influence the effect of verapamil in hypertensive patients with mild renal insufficiency.

Authors:  L M Ruilope; M C Casal; L Guerrero; J M Alcázar; M L Férnandez; V Lahera; J L Rodicio
Journal:  Drugs       Date:  1992       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.